Hostname: page-component-78c5997874-ndw9j Total loading time: 0 Render date: 2024-11-18T10:43:19.821Z Has data issue: false hasContentIssue false
  • English
  • Français

Clinical Trial of Promazine Hydrochloride and Acetylpromazine in Chronic Schizophrenic Patients

Published online by Cambridge University Press:  08 February 2018

R. Urquhart  and
A. D. Forrest
R. Urquhart
Affiliation:
Royal Edinburgh Hospital
A. D. Forrest
Affiliation:
Department of Psychological Medicine, University of Edinburgh
Get access Rights & Permissions [Opens in a new window]

Extract

The last few years have produced an extensive literature on the chemotherapy of schizophrenia (Foote, 1955; Shepherd and Watt, 1956; Wing, 1956; Kinross-Wright, 1957). Enthusiastic reports continue to appear in the American journals (Feldman, 1957; Winkelman, 1957) whereas a more cautious note is usually struck in psychiatric papers published in this country. The value of reserpine is now generally accepted (Moore and Mankin, 1957; Elkes, 1957) but it is not without dangerous side-effects (Wardell, 1957). Chlorpromazine is now used extensively and is probably a safer drug; the danger of jaundice has not proved to be a real contra-indication to the use of the drug. However, reports of deaths during treatment with chlorpromazine have been published (Stënback, 1956).

Type
Original Articles
Information
Journal of Mental Science , Volume 105 , Issue 438 , January 1959 , pp. 260 - 264
Copyright
Copyright © Royal College of Psychiatrists, 1959 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Bateson, G., et al., “Towards a communication theory of schizophrenia”, Behavioural Sciences, 1956, 1.Google Scholar
2. Bickford, J. A. R., Lancet, 1955, 2, 969.CrossRefGoogle Scholar
3. Clark, D. H., ibid., 1956, 2, 1005.Google Scholar
4. Elkes, C., J. Ment. Sci., 1957, 103, 464.CrossRefGoogle Scholar
5. Fabing, H. D., ibid., 1958, 104, 573.Google Scholar
6. Feldman, P. D., Amer. J. Psychiat., 1957, 114, 237.CrossRefGoogle Scholar
7. Foote, E. S., Brit. Med. J., 1955, i, 1192.CrossRefGoogle Scholar
8. Forrest, A. D., J. Ment. Sci., 1957, 103, 614.CrossRefGoogle Scholar
9. Freeman, T., Cameron, J. L., and McGhie, A., Chronic Schizophrenia, 1958. London: Tavistock Publications.Google Scholar
10. Houston, F., Brit. Med. J., 1956, i, 949.CrossRefGoogle Scholar
11. Kinross-Wright, V., Med. Clin. N. Amer., 1957, 41, 295.CrossRefGoogle Scholar
12. Moore, J. P. N., and Mankin, E. A., Brit. Med. J., 1957, i, 8.CrossRefGoogle Scholar
13. Shepherd, M., and Watt, O. C., J. Neurol. Neurosurg. Psychiat., 1956, 19, 232.CrossRefGoogle Scholar
14. Stënback, A., Nord. Med. (Nordisk Medicin), 1956, 56, 1622.Google Scholar
15. Wardell, D. W., Amer. J. Psychiat., 1957, 113, 745.CrossRefGoogle Scholar
16. Wing, L., J. Ment. Sci., 1956, 102, 530.CrossRefGoogle Scholar
17. Winkelman, N. W., Amer. J. Psychiat, 1957, 113, 961.CrossRefGoogle Scholar
Submit a response

eLetters

No eLetters have been published for this article.